Cancer Research Cell Death Mechanisms and Cancer Therapy  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 54, 362-364, January 15, 1994]
© 1994 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moul, J. W.
Right arrow Articles by Sesterhenn, I. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moul, J. W.
Right arrow Articles by Sesterhenn, I. A.

Percentage of Embryonal Carcinoma and of Vascular Invasion Predicts Pathological Stage in Clinical Stage I Nonseminomatous Testicular Cancer1

Judd W. Moul2, William F. McCarthy, Eduardo B. Fernandez and Isabell A. Sesterhenn

Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799 [J. W. M., W. F. M.]; Urology Services, Department of Surgery and Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC 20307-5001 [E. B. F., J. W. M.]; and Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000 [I. A. S.]

2 Supported in part by Grant R090BJ from the Uniformed Services University of the Health Sciences and by Grant 2873 from the Department of Clinical Investigation, Walter Reed Army Medical Center. To whom requests for reprints should be addressed, at (Department of Surgery, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4799.

We analyzed 92 clinical stage I nonseminomatous testicular germ cell tumors for primary tumor histological factors that would distinguish true pathological stage I disease (N = 54) from those patients who harbored occult disease and actually were later found to have pathological stage II disease (N = 38). Primary tumor pathological material was analyzed for vascular invasion, lymphatic invasion, tunical invasion, and quantitative determination of percentage of the primary tumor composed of embryonal carcinoma, yolk sac carcinoma, teratoma, and seminoma. Univariate logistic regression analyses revealed that vascular invasion (P = 0.0001), percentage of embryonal carcinoma (P = 0.0001), lymphatic invasion (P = 0.0001), and tunical invasion (P = 0.0013) were higher in pathological stage II and that percentage of teratoma (P = 0.0001) and of yolk sac carcinoma (P = 0.0174) were higher in stage I. Percentage of seminoma was not significant. Individually, these parameters were able to correctly predict occult disease 66.3 to 80.4% of the time. In multivariate logistic regression analysis, only vascular invasion and percentage of embryonal carcinoma remained significant, and a model using these two variables was able to correctly predict stage 85.9% of the time. Vascular invasion and determination of percentage of embryonal carcinoma should be assessed for all clinical stage I nonseminomatous germ cell tumor patients and the model presented herein can be used clinically to predict the likelihood of occult disease and dictate therapy.

1 The opinions and assertions contained herein are the private views of the authors and are not to be construed as reflective of the official views of the United States Army or Department of Defense.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/28/93. Accepted 11/26/93.




This article has been cited by other articles:


Home page
Ann OncolHome page
P. Maroto, X. G. del Muro, J. Aparicio, L. Paz-Ares, J. A. Arranz, J. Guma, J. Terrassa, J. Barnadas, J. Dorta, and J. R. Germa-Lluch
Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours
Ann. Onc., December 1, 2005; 16(12): 1915 - 1920.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
Y. Vergouwe, E. W. Steyerberg, M. J.C. Eijkemans, P. Albers, and J. D. F. Habbema
Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review
J. Clin. Oncol., November 15, 2003; 21(22): 4092 - 4099.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1994 by the American Association for Cancer Research.